Rabeprazole Sodium for Injection (Aobo Ping®) is the first to launch in China

Shenzhen, [September 29] C&O today announces the launch of its first next-generation proton pump inhibitor, Rabeprazole Sodium for Injection (Aobo Ping®), in China. Aubergine® is a self-developed product of C&O.

Peptic ulcers are a globally prevalent disease with a high incidence of about 10%. A high percentage of patients with bleeding peptic ulcers, 43.4%, are at high risk of rebleeding. The launch of Rabeprazole Sodium for Injection (Aobo Ping®) provides a new treatment option for patients with bleeding peptic ulcers and for healthcare providers treating peptic ulcers, meeting a growing market demand.

Proton pump inhibitors (PPIs) act to suppress gastric acid secretion by blocking the final stage of gastric acid secretion. Aobo Ping® developed by C&O, a second-generation proton pump inhibitor, is the first new drug to be marketed in China. The new drug product offers a new option for the treatment of patients with non-oral bleeding gastric ulcers and duodenal ulcers. Compared with other injectable proton pump inhibitors, Aobo Ping® is characterized by faster onset of acid suppression and longer lasting potency; because rabeprazole is less susceptible to metabolism by CYP450 drug metabolizing enzymes, Aobo Ping® also has the advantages of small individual differences in efficacy and fewer drug interactions..

As a listed pharmaceutical company integrating R&D, production and sales of new drugs, C&O is committed to creating more drugs with better efficacy for patients and making great contributions to saving patients’ lives, and improving their health and human health.